Notably, NTZ depleted β-catenin in colon cancer cells with mutant APC or β-catenin, For cancer treatment, a new use for an “old drug” has many benefits without the limitation of unknown safety and toxicity profiles [35]. The gene discussed is APC; the disease is colonic neoplasm.